Rheumatology Advance Access published online on March 9, 2005
Rheumatology, doi:10.1093/rheumatology/keh580
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Medicine, Division of Rheumatology, McGill University, Montréal, Québec, Canada
* To whom correspondence should be addressed. Objective. We have shown that SLE patients in Canada and the UK incurred 20% and 13% lower health costs than those in the US, respectively, but did not experience worse outcomes as expressed by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. We now compare change in quality of life in these patients. Patients and methods. Seven hundred and fifteen SLE patients (Canada 231, US 269, UK 215) completed the SF-36 annually over four years. The annual change in the SF-36 Physical and Mental Component Summary (PCS and MCS) scores over the course of the study were summarized by estimating a linear trend for each individual patient using hierarchical modelling. Cross-country comparison of the slopes in the PCS and MCS scores was then performed using simultaneous regressions. Results. The estimated mean annual changes (95% credible interval [CrI]) in the PCS scores in Canada, the US, and the UK were 0.18 (-0.07, 0.43), -0.05 (-0.27, 0.17), and 0.03 (-0.20, 0.27), respectively; the mean annual changes in the MCS scores were 0.15 (-0.04, 0.34), 0.23 (0.09, 0.37), and 0.08 (-0.10, 0.27), respectively. Regression results showed that the mean annual changes in PCS and MCS scores did not substantially differ across countries. Conclusion. Quality of life remained stable across countries. Despite Canadian and British patients incurring lower health costs, on average, patients experienced similar changes in physical and mental well-being.
Received July 24, 2004
Accepted January 26, 2005
Concise Report
The systemic lupus erythematosus tri-nation study: longitudinal changes in physical and mental well-being
2 McGill University, Montréal, Québec, Canada, Department of Medicine (Division of Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, USA
3 Department of Medicine, Division of Rheumatology and Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA
4 Centre for Rheumatology, Department of Medicine, University College London, London, UK
5 Department of Rheumatology, Division of Immunity and Infection, University of Birmingham, Birmingham, UK
6 Department of Medicine (Division of Rheumatology), Hôpital Notre-Dame, Université de Montréal, Montréal, Québec, Canada
7 Department of Medicine, Division of Clinical Epidemiology, McGill University, Montréal, Québec, Canada; McGill University Health Centre, Department of Economics, McGill University, Montréal, Québec, Canada
8 Department of Medicine, Division of Clinical Epidemiology, McGill University, Montréal, Québec, Canada; McGill University Health Centre, Department of Biostatistics, McGill University, Montréal, Québec, Canada
9 Department of Medicine, Division of Clinical Epidemiology, McGill University, Montréal, Québec, Canada
10 Department of Medicine (Division of Rheumatology) and Department of Epidemiology, University of Toronto, Toronto, Ontario, Canada
11 Arthritis Research Centre of Canada and Department of Medicine, University of British Columbia, Vancouver, BC, Canada
12 Department of Medicine, Division of Clinical Epidemiology, McGill University, Montréal, Québec, Canada; Department of Medicine, Division of Clinical Immunology/Allergy, McGill University, Montréal, Québec, Canada
A. E. Clarke, E-mail: ann.clarke{at}mcgill.ca
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. J. COLANGELO, J. E. POPE, and C. PESCHKEN The Minimally Important Difference for Patient Reported Outcomes in Systemic Lupus Erythematosus Including the HAQ-DI, Pain, Fatigue, and SF-36 J Rheumatol, October 1, 2009; 36(10): 2231 - 2237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. APPENZELLER, A. E. CLARKE, P. PANOPALIS, L. JOSEPH, Y. ST. PIERRE, and T. LI The Relationship Between Renal Activity and Quality of Life in Systemic Lupus Erythematosus J Rheumatol, May 1, 2009; 36(5): 947 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Dussan, L Magder, R. Brodsky, R. Jones, and M Petri High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures Lupus, December 1, 2008; 17(12): 1079 - 1085. [Abstract] [PDF]
|
|
|
|
 |
|
 A. E. Clarke, P. Panopalis, M. Petri, S. Manzi, D. A. Isenberg, C. Gordon, J.-L. Senecal, L. Joseph, Y. St Pierre, and T. Li SLE patients with renal damage incur higher health care costs Rheumatology, March 1, 2008; 47(3): 329 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A M Bertoli, M Fernandez, G S Alarcon, L M Vila, J D Reveille, and for the LUMINA Study Group Systemic lupus erythematosus in a multiethnic US cohort LUMINA (XLI): factors predictive of self-reported work disability Ann Rheum Dis, January 1, 2007; 66(1): 12 - 17. [Abstract] [Full Text] [PDF]
|
|